Drucken
vwd group

12.07.2018 - 18:05

DGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018



DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results


BB Biotech AG reports preliminary results for 1H 2018


12-Jul-2018 / 18:05 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Media Release, July 12, 2018

 
BB Biotech AG reports preliminary results for 1H 2018

 

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2018.

 

Based on preliminary unaudited consolidated results, BB Biotech closed the first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the corresponding period of the previous year). As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.

 

BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the corresponding period.

 

 

The interim report as of June 30, 2018 will be published on July 20, 2018.

 

 

 

 
For further information:

 
Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Dr. Silvia Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

 
Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07

Tanja Chicherio, tch@bellevue.ch

 
www.bbbiotech.com

 

 
Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.








12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de























Language: English
Company: BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX





 
End of Announcement DGAP News Service




703867  12-Jul-2018 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=703867&application_name=news&site_id=real_vwd

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de